Today: 16 April 2026
Bank of America stock price slips in premarket as CPI looms and Epstein lawsuit hangs over shares
13 February 2026
2 mins read

Bank of America stock price slips in premarket as CPI looms and Epstein lawsuit hangs over shares

New York, February 13, 2026, 08:17 (EST) — Premarket

  • Bank of America shares slipped a bit in premarket, coming off a steep decline the previous session.
  • A U.S. judge ruled that the claims against the bank are sufficient for the Epstein-linked proposed class action to proceed.
  • All eyes shift to the U.S. January CPI report, scheduled for release at 8:30 a.m. ET. Investors are bracing.

Bank of America Corp slipped roughly 0.3% ahead of the bell Friday, following a 2.47% drop to $52.52 at Thursday’s close.

Timing is key here. Wall Street has its eye on the January U.S. consumer price report set for 8:30 a.m. ET, and bank shares are known to react sharply when interest rate expectations shift. For lenders, net interest income — that’s the spread between loan earnings and deposit costs — usually tracks the path of interest rates.

Stock index futures in the U.S. hovered near flat as the market braced for the inflation release, following an AI-driven tumble. Rate bets stayed fixed on a possible cut in June. Bob Savage, who heads markets macro strategy at BNY, pointed out in a note, “The central question for equity investors is whether today’s surge in capex can translate into durable earnings growth.” Reuters

Bank of America faces fresh legal heat after a U.S. judge found that claims the bank “recklessly disregarded” signs of Jeffrey Epstein’s sex trafficking are solid enough to keep a proposed class action alive. The ruling also pins down a trial date: May 11. The bank says it welcomes a thorough review of the facts. Reuters

Thursday saw Bank of America drop along with the rest of the financial sector. JPMorgan Chase slipped 2.63%, Wells Fargo lost 2.99%. Major U.S. indexes sank sharply.

Rates are still the market’s other major swing factor. According to a Reuters survey, long-dated Treasury yields are expected to stay put for now, then pick up later this year. Investors have kept a close eye on the 10-year, which has barely budged from its 4.0%-4.3% range. “There’s nothing really to drive us out of this range,” said John Madziyire of Vanguard. But BlackRock’s Jean Boivin sees a potential jolt: “Once we see some evidence of the opposite, it’ll come as a wake-up call with some volatility.” Meghan Swiber at Bank of America pointed out the awkward mix of cutting rates while the Fed continues to trim its balance sheet. Reuters

Bank stock traders have their eyes on the yield curve—the difference between short- and long-term yields—which plays into lending margins and demand for fresh credit. Volatility’s impact isn’t one-way: some days it boosts trading desk results, other days it rattles risk appetite across the board.

A CPI surprise to the upside? Yields probably move higher, and that tends to push back the timeline for rate cuts—a combo that tightens financial conditions and stirs up concerns over loan appetite and possible credit losses down the road. A softer CPI number, on the other hand, breathes life into rate-cut hopes, though it may also weigh on net interest income forecasts if markets jump to price in lower rates more swiftly.

Stock Market Today

  • ASX Penny Stocks to Watch April 2026: Frontier Energy and Imricor Medical Systems
    April 15, 2026, 10:34 PM EDT. As the ASX approaches 9,000 points, penny stocks offer potential growth amid mixed market signals. Frontier Energy Limited (ASX:FHE), valued at A$146.27 million, targets renewable energy with a promising Waroona Project expected to yield A$32 million annually from 2027. The company is debt-free and recently appointed Jamie Cullen as Executive Chairman. Imricor Medical Systems (ASX:IMR), a medical device firm with a A$632.27 million market cap, posted US$0.29 million revenue in 2025. Despite a -219.72% return on equity, it holds more cash than debt and expects 89% revenue growth and a 32% stock price rise. Both stocks remain pre-revenue but show strong leadership and financial stability amid local and global market challenges.

Latest article

Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

16 April 2026
Norse Atlantic Airways has canceled all planned summer flights from Los Angeles to London Gatwick, Paris, and Rome, citing surging jet fuel costs. The airline launched a $110 million rights issue, secured a $70 million bridge loan, and withdrew its 2026 outlook. Routes disappeared from booking systems on April 14. Norse had been the only scheduled operator on the Gatwick-Los Angeles route.
S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

16 April 2026
The S&P 500 closed at a record 7,022.95 and the Nasdaq at 24,016.02 on Wednesday, erasing losses from the March selloff tied to the Feb. 28 conflict. Bank of America reported $8.6 billion in first-quarter net income, up 17%, while Morgan Stanley posted record revenue. Talks between Washington and Tehran raised hopes for easing oil supply fears, but Brent crude stayed elevated at $94.93 a barrel.
Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

16 April 2026
China is considering export restrictions on advanced solar-manufacturing equipment to the U.S., potentially affecting Tesla’s plans for new factories, sources told Reuters. Tesla aims to buy $2.9 billion in solar-panel equipment from China and expand U.S. solar production. China produces over 80% of global solar panel components. No final decision has been made, and consultations remain preliminary.
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

15 April 2026
Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
Algorhythm Holdings (RIME) stock price jumps in premarket as SemiCab AI freight claim keeps traders on edge
Previous Story

Algorhythm Holdings (RIME) stock price jumps in premarket as SemiCab AI freight claim keeps traders on edge

Performance Food Group stock steadies near $98 after an 8% surge — here’s what Wall Street is watching
Next Story

Performance Food Group stock steadies near $98 after an 8% surge — here’s what Wall Street is watching

Go toTop